Taken together, our results demonstrate that specific fluid biomarkers can partly substitute for Aβ-PET and emphasize that altered metabolism of soluble Aβ is a key feature of the overall presence of Aβ pathology, while altered metabolism of soluble P-tau is related to the magnitude of Aβ pathology within the AD continuum. The gene discussed is MAPT; the disease is Alzheimer disease.